Galectin Therapeutics
GALT
75 hedge funds and large institutions have $25.3M invested in Galectin Therapeutics in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 13 increasing their positions, 20 reducing their positions, and 20 closing their positions.
144% more call options, than puts
Call options by funds: $1.8M | Put options by funds: $737K
0% more funds holding
Funds holding: 75 → 75 (0)
0% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 20
3.78% less ownership
Funds ownership: 17.41% → 13.62% (-3.8%)
35% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 20
52% less capital inflows, than outflows
Capital inflows: $6.09M | Capital outflows: $12.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.02M |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$599K |
| 3 |
E
Ergoteles
New York
|
+$495K |
| 4 |
HF
HRT Financial
New York
|
+$373K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$351K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.62M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$1.16M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$843K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$384K |
GALT Hedge Fund Activity: Q2 2021 in Review
75 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2021, worth a combined $25.3M — up 11% from $22.7M a quarter earlier.
Fund positioning in GALT was balanced in Q2 2021: 20 funds opened new positions, 20 closed out, 13 added to existing stakes and 20 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.02M. The largest seller was BlackRock, cutting an estimated $6.5M.
- 75 institutional investors held Galectin Therapeutics (GALT) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $25.3M of Galectin Therapeutics stock for Q2 2021, up 11% quarter-over-quarter.
- 20 funds opened new Galectin Therapeutics positions in Q2 2021 and 20 closed out, a net change of 0 holders.
- The largest Galectin Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $2.02M added.
- The largest Galectin Therapeutics seller in Q2 2021 was BlackRock, an estimated $6.5M sold.
Based on aggregated 13F filings for Q2 2021.